Medicilon offers fully integrated pharmaceutical services for the global scientific community and is focused on providing an exceptional client-centered experience and advancing the drug discovery process. Since the founding of our company in 2004, our integrated services across biology, chemistry and preclinical services are uniquely designed to help clients develop their research and discovery programs from the initial idea stage to the IND filing phase.
Our headquarters is located in Zhangjiang High-Tech Park in Shanghai, China, with an additional facility in Chuansha Economic Park, Shanghai, China. We occupy over 200,000 Sq. ft. in lab space and have over 300 employees cross biology, chemistry and preclinical research. Over 50% employees have M.S. and Ph. D. degrees, over 10% have foreign education and/or work experiences.
Medicilon has been recognized as one of the top drug discovery contract research organizations (CRO) in China and is managed by a team of scientists with a wealth of experience in US-based pharmaceutical and biotechnology companies. As our areas of expertise and service capabilities continue to expand, more and more pharmaceutical and biotechnology companies have taken advantage of our integrated drug discovery and development services.
Our headquarters is located in Zhangjiang High-Tech Park in Shanghai, China, with an additional facility in Chuansha Economic Park, Shanghai, China. We occupy over 200,000 Sq. ft. in lab space and have over 300 employees cross biology, chemistry and preclinical research. Over 50% employees have M.S. and Ph. D. degrees, over 10% have foreign education and/or work experiences.
Medicilon has been recognized as one of the top drug discovery contract research organizations (CRO) in China and is managed by a team of scientists with a wealth of experience in US-based pharmaceutical and biotechnology companies. As our areas of expertise and service capabilities continue to expand, more and more pharmaceutical and biotechnology companies have taken advantage of our integrated drug discovery and development services.
Location: China, Shanghai, Pudong
Employees: 501-1000
Phone: +1 339-223-6033
Founded date: 2004
Mentions in press and media 14
| Date | Title | Description |
| 29.05.2025 | Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence | BOSTON, May 29, 2025 /PRNewswire/ -- On May 20, Medicilon Preclinical Research (Shanghai) LLC ("Medicilon") announces that it has successfully passed an on-site inspection by the FDA. The company receives an official Establishment... |
| 20.12.2024 | Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer | BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development,... |
| 09.12.2024 | Medicilon large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development | With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of... |
| 31.08.2024 | Medicilon's New R&D Center: A Strategic Leap in Pharmaceutical Innovation | In the bustling heart of Massachusetts, Medicilon USA Corp has taken a bold step forward. The company has officially opened its second research and development (R&D) center in Lexington. This move is not just a geographical expansion; i... |
| 29.08.2024 | Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts | BOSTON, Aug. 29, 2024 /PRNewswire/ -- In August 2024, Medicilon USA Corp (Medicilon) officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and ... |
| 29.08.2024 | Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts | BOSTON, Aug. 29, 2024 /PRNewswire/ -- In August 2024, Medicilon USA Corp (Medicilon) officially commenced operations at its second R&D center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and ... |
| 31.07.2024 | Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs | BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement. The cooperative efforts ... |
| 11.03.2024 | Medicilon has appointed Dr. Qingcong Lin as President of Medicilon USA Corp., further deepening the global strategic layout | BOSTON, March 11, 2024 /PRNewswire/ -- Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and ef... |
| 09.01.2024 | Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit | BOSTON, Jan. 9, 2024 /PRNewswire/ -- Recently, Medicilon appoints Dr. Zhang Haizhou as President of Preclinical R&D Unit. Medicilon, the pioneer integrated pharmaceutical R&D preclinical services that offers chemistry, DMPK/PD, CMC,... |
| 28.11.2023 | Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award | BOSTON, Nov. 28, 2023 /PRNewswire/ -- Dr. Liu Jian, President of the Drug Discovery Division at Medicilon, has been awarded the Thomas Alva Edison Patent Award for 2023 from the New Jersey Research and Development Committee. This recognitio... |
Show more